Quest Diagnostics (DGX) Q4 Earnings and Revenues Top Estimates

Zacks

Quest Diagnostics (DGX) came out with quarterly earnings of $2.23 per share, beating the Zacks Consensus Estimate of $2.19 per share. This compares to earnings of $2.15 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 1.83%. A quarter ago, it was expected that this medical laboratory operator would post earnings of $2.26 per share when it actually produced earnings of $2.30, delivering a surprise of 1.77%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Quest Diagnostics, which belongs to the Zacks Medical - Outpatient and Home Healthcare industry, posted revenues of $2.62 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.96%. This compares to year-ago revenues of $2.29 billion. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Quest Diagnostics shares have added about 3% since the beginning of the year versus the S&P 500's gain of 2.7%.

What's Next for Quest Diagnostics?

While Quest Diagnostics has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Quest Diagnostics: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $2.21 on $2.61 billion in revenues for the coming quarter and $9.71 on $10.67 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Outpatient and Home Healthcare is currently in the top 36% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Astrana Health, Inc. (ASTH), has yet to report results for the quarter ended December 2024.

This company is expected to post quarterly earnings of $0.09 per share in its upcoming report, which represents a year-over-year change of -65.4%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Astrana Health, Inc.'s revenues are expected to be $630.99 million, up 78.7% from the year-ago quarter.

Zacks Investment Research

Risk Warnings and Disclaimers

You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.

Add to Favorites

Apple, Visa, Intel set to report earnings Thursday, along with 100+ more

Investing.com

Earnings season continues, with a flurry of major companies set to release their financial results for the upcoming trading day. Leading the pack are tech giants Apple, Visa, and Intel, along with a host of other notable firms across various sectors. Here's a preview of what to expect as the market prepares for another busy day of earnings reports.

Earnings Before the Open:

• NetScout Systems (NASDAQ:NTCT): EPS est. $0.725, Revenue est. $220.97M

• Dynatrace Holdings LLC (NYSE:DT): EPS est. $0.3302, Revenue est. $426.46M

• Cardinal Health (NYSE:CAH): EPS est. $1.77, Revenue est. $54.56B

• Parkerhannifin (NYSE:PH): EPS est. $6.23, Revenue est. $4.81B

• Allegro (WA:ALEP) Microsystems Inc (ALGM): EPS est. $0.0644, Revenue est. $176.36M

• 1-800 FLOWERS.COM (NASDAQ:FLWS): EPS est. $1.2, Revenue est. $801.91M

• Malibu Boats Inc (NASDAQ:MBUU): EPS est. $0.2688, Revenue est. $194.36M

• A.O Smith Corp (NYSE:AOS): EPS est. $0.898, Revenue est. $952.28M

• Dow Chemical (NYSE:DOW): EPS est. $0.294, Revenue est. $10.58B

• Comcast Corp New (NASDAQ:CMCSA): EPS est. $0.8612, Revenue est. $31.61B

• Mastercard Cl A (NYSE:MA): EPS est. $3.7, Revenue est. $7.4B

• Consol Energy (NYSE:CNX): EPS est. $0.4279, Revenue est. $424.4M

• Sherwinwilliams (NYSE:SHW): EPS est. $2.07, Revenue est. $5.33B

• Valero Energy (NYSE:VLO): EPS est. $0.4268, Revenue est. $30.36B

• Marsh & Mclennan (MMC): EPS est. $1.77, Revenue est. $5.93B

• Murphy Oil Corp (NYSE:MUR): EPS est. $0.6872, Revenue est. $763.43M

• RPC Inc. (NYSE:RES): EPS est. $0.0775, Revenue est. $329.29M

• STMicroelectronics NV (NYSE:STM): EPS est. $0.3541, Revenue est. $3.31B

• Alliance Data Systems (NYSE:BFH): EPS est. $0.3209, Revenue est. $966.44M

• Check Point Software Tech Lt (NASDAQ:CHKP): EPS est. $2.65, Revenue est. $698.43M

• Altria Group (NYSE:MO): EPS est. $1.29, Revenue est. $5.04B

• Avery Dennison (NYSE:AVY): EPS est. $2.39, Revenue est. $2.2B

• Thermo Fisher Sc (NYSE:TMO): EPS est. $5.95, Revenue est. $11.29B

• Quest Diag (NYSE:DGX): EPS est. $2.19, Revenue est. $2.58B

• United Parcel (NYSE:UPS): EPS est. $2.52, Revenue est. $25.41B

• Pulte Homes Inc (NYSE:PHM): EPS est. $3.27, Revenue est. $4.65B

• Roper Industries (NASDAQ:ROP): EPS est. $4.73, Revenue est. $1.84B

• Kearny Financial (NASDAQ:KRNY): EPS est. $0.11, Revenue est. $39.37M

• SunCoke Energy Inc (NYSE:SXC): EPS est. $0.205, Revenue est. $380.95M

• Nokia Corp-Exch (NYSE:NOK): EPS est. $0.1403, Revenue est. $6.2B

• Manpower Inc (NYSE:MAN): EPS est. $1.01, Revenue est. $4.48B

• Cigna Corp (NYSE:CI): EPS est. $7.79, Revenue est. $63.16B

• First Cash Financial (NASDAQ:FCFS): EPS est. $2.02, Revenue est. $898.74M

• Intl Paper Co (NYSE:IP): EPS est. $-0.0675, Revenue est. $4.73B

• CSW Industrials Inc (NASDAQ:CSWI): EPS est. $1.43, Revenue est. $191.87M

• Trane Technologies plc (NYSE:TT): EPS est. $2.52, Revenue est. $4.77B

• Royal Dutch Shell A PLC (NYSE:SHEL): EPS est. $1.74, Revenue est. $69.22B

• Silicom Ltd (NASDAQ:SILC): EPS est. $-0.33, Revenue est. $14.64M

• Caterpillar (NYSE:CAT): EPS est. $5.06, Revenue est. $16.64B

• Brookfield Infrastructure (NYSE:BIPC) Partner (BIP): EPS est. $0.1769, Revenue est. $1.98B

• Dover Corp (NYSE:DOV): EPS est. $2.08, Revenue est. $1.96B

• S&T Bancorp (STBA): EPS est. $0.77, Revenue est. $96.88M

• The Blackstone Group (NYSE:BX): EPS est. $1.43, Revenue est. $3.78B

• First Citizens Banc Corp (NASDAQ:CIVB): EPS est. $0.535, Revenue est. $39.99M

• First Foundation Inc (NYSE:FFWM): EPS est. $0.037, Revenue est. $65.77M

• ScanSource (NASDAQ:SCSC): EPS est. $0.8833, Revenue est. $866.85M

• New York Community Bancorp ({{8886|FLNYSE:FLG): EPS est. $-0.5235, Revenue est. $571.85M

• Ramco-Gershenson Properties Trust (NYSE:RPT): EPS est. $-0.39, Revenue est. $6.19M

• Schneider National Inc (NYSE:SNDR): EPS est. $0.1957, Revenue est. $1.35B

• Tractor Supply Company (NASDAQ:TSCO): EPS est. $0.4542, Revenue est. $3.79B

• ConnectOne Bancorp Inc (NASDAQ:CNOB): EPS est. $0.445, Revenue est. $68.66M

• Sth West Airlines (NYSE:LUV): EPS est. $0.3883, Revenue est. $6.91B

• Brunswick Corp (NYSE:BC): EPS est. $0.2182, Revenue est. $1.05B

• Berkshire Hills B (NYSE:BHLB): EPS est. $0.5533, Revenue est. $107.7M

• First Merchants Corp (NASDAQ:FRME): EPS est. $0.885, Revenue est. $167.76M

• Cullen/Frost Bankers Inc (NYSE:CFR): EPS est. $2.16, Revenue est. $530.92M

• Kirby Corp (NYSE:KEX): EPS est. $1.37, Revenue est. $803.28M

• Onewater Marine (NASDAQ:ONEW): EPS est. $-0.855, Revenue est. $337.52M

• Mobileye Global (NASDAQ:MBLY): EPS est. $0.21, Revenue est. $670.90M

• Rogers (NYSE:ROG) communicat (RCI): EPS est. $0.9641, Revenue est. $3.88B

• Harris Corporation (NYSE:LHX): EPS est. $3.44, Revenue est. $5.5B

• Northrop Grumman (NYSE:NOC): EPS est. $6.34, Revenue est. $10.96B

• Carpenter Technology Corp (NYSE:CRS): EPS est. $1.62, Revenue est. $724.42M

• Asbury Automotive Group Inc (NYSE:ABG): EPS est. $6.08, Revenue est. $4.18B

• Sanofi (NASDAQ:SNY): EPS est. $0.7836, Revenue est. $12.38B

• Sirius Satellite Radio Inc (NASDAQ:SIRI): EPS est. $0.0772, Revenue est. $2.22B

• Roche Holding Ltd (OTC:RHHBY): EPS est. $1.34, Revenue est. $17.84B

• ABB Ltd ADR (ABBNY): EPS est. $0.5629, Revenue est. $8.44B

• Banco Bilbao Viscaya Argentaria SA (NYSE:BBVA (BME:BBVA)): EPS est. $0.3684, Revenue est. $9.2B

• AB Electrolux (ST:ELUXa) (ELUXY): EPS est. $0.2937, Revenue est. $3.32B

• Axfood ADR (AXFOY): EPS est. $0.204, Revenue est. $2.05B

• Royal KPN NV (OTC:KKPNY): EPS est. $0.0701, Revenue est. $1.59B

• Abb Ltd (SIX:ABBN) Zuerich (ABLZF): EPS est. $0.5629, Revenue est. $8.44B

• Oshkosh corporati (NYSE:OSK): EPS est. $2.19, Revenue est. $2.42B

• Royal Dutch Shell (LON:SHEL) Pl (RYDAF): EPS est. $0.8705, Revenue est. $69.22B

• Canon (CAJPY): EPS est. $0.4854, Revenue est. $8.34B

• Evolution Gaming Group (ST:EVOG) AB ADR (EVVTY): EPS est. $1.41, Revenue est. $573.78M

• TeliaSonera AB (TLSNY): EPS est. $0.0742, Revenue est. $2.18B

• Marine Products Corp (NYSE:MPX): EPS est. $0.05, Revenue est. $46.3M

Earnings After the Close:

• Baker Hughes (NASDAQ:BKR): EPS est. $0.6286, Revenue est. $7.08B

• Symantec Corp (NASDAQ:GEN): EPS est. $0.5506, Revenue est. $985.11M

• Kla-tencor Corp (NASDAQ:KLAC): EPS est. $7.75, Revenue est. $2.94B

• ResMed Inc (NYSE:RMD): EPS est. $2.32, Revenue est. $1.27B

• Jds Uniphase Corp (NASDAQ:VIAV): EPS est. $0.0999, Revenue est. $259.99M

• Atlassian Corp Plc (NASDAQ:TEAM): EPS est. $0.62, Revenue est. $1,023M

• Apple Computer Inc (NASDAQ:AAPL): EPS est. $2.36, Revenue est. $124.99B

• Visa Inc (NYSE:V): EPS est. $2.66, Revenue est. $9.35B

• Intel Corp (NASDAQ:INTC): EPS est. $0.1161, Revenue est. $13.83B

• Ppg Industries (NYSE:PPG (WA:IBSP)): EPS est. $1.65, Revenue est. $4.07B

• The Bancorp (NASDAQ:TBBK): EPS est. $1.15, Revenue est. $133.01M

• Olin Corp (NYSE:OLN): EPS est. $0.0015, Revenue est. $1.56B

• Deckers Outdoor Corp (NYSE:DECK): EPS est. $2.46, Revenue est. $1.7B

• Arthur J. Gallagher & Co (AJG): EPS est. $2.06, Revenue est. $2.71B

• Boot Barn Holdin (NYSE:BOOT): EPS est. $2.05, Revenue est. $592.71M

• Hartford Finl (NYSE:HIG): EPS est. $2.67, Revenue est. $6.91B

• Us Steel Corp (X): EPS est. $0.0375, Revenue est. $3.6B

• Credit Acceptance (NASDAQ:CACC): EPS est. $7.93, Revenue est. $522.6M

• LPL Investment Ho (NASDAQ:LPLA): EPS est. $3.96, Revenue est. $3.27B

• Coursera (COUR): EPS est. $0.0425, Revenue est. $176.49M

• Ameris Bancorp (NYSE:ABCB): EPS est. $1.18, Revenue est. $276.17M

• Standex International Corp (NYSE:SXI): EPS est. $1.85, Revenue est. $187.61M

• Eastman Chem (NYSE:EMN): EPS est. $1.61, Revenue est. $2.28B

• Cavco Industries (NASDAQ:CVCO): EPS est. $4.89, Revenue est. $480.15M

• DeVry Inc (NYSE:ATGE): EPS est. $1.38, Revenue est. $416.26M

• Beazer Homes USA Inc (NYSE:BZH): EPS est. $0.3075, Revenue est. $464.92M

• Weyerhaeuser (NYSE:WY): EPS est. $0.0481, Revenue est. $1.72B

• Fed Investors (NYSE:FHI (TSX:FHI)): EPS est. $0.9794, Revenue est. $420.32M

• Financial Institutions (FISI): EPS est. $0.47, Revenue est. $52.1M

• PennyMac Mortgage Investment Trust (NYSE:PMT): EPS est. $0.3603, Revenue est. $97.8M

• Hilltop Holdings Inc (NYSE:HTH): EPS est. $0.295, Revenue est. $289.76M

• Pennymac Fnl Ser (NYSE:PFSI): EPS est. $3.03, Revenue est. $531.7M

• Orchid Isla (ORC): EPS est. $-0.015, Revenue est. $1.83M

• Appfolio Inc (NASDAQ:APPF): EPS est. $0.9397, Revenue est. $199.86M

• Finwise Bancorp (FINW): EPS est. $0.185, Revenue est. $21.07M

• Stellar Bancorp (STEL): EPS est. $0.494, Revenue est. $107.51M

• SkyWest (NASDAQ:SKYW): EPS est. $1.8, Revenue est. $907.54M

• Resmed ADR (RSMDF): EPS est. $0.2324, Revenue est. $1.27B

Check back daily for updates and insights into the earnings season and real-time results here and here.

Do you want to trade the earnings of the biggest companies like a pro? Then get InvestingPro now and access over 1000 metrics that will give you a significant advantage in the shark tank that is Wall Street. Click here.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Risk Warnings and Disclaimers

Add to Favorites

Officer Kumar Surrenders 7210 Of Astrana Health Inc [Asth]

Reuters

Astrana Health

-0.23%

Risk Warnings and Disclaimers

Add to Favorites

Dj Officer Kumar Surrenders 7210 Of Astrana Health Inc >Asth

Reuters

Astrana Health

-0.23%

Risk Warnings and Disclaimers

Add to Favorites

Quest Diagnostics Q4 Earnings Preview: What's in Store for the Stock?

Zacks

Merit Medical Systems

-1.72%

Exelixis

+0.70%

Quest Diagnostics DGX is set to release its fourth-quarter 2024 results on Jan. 30 before the market opens.

Find the latest EPS estimates and surprises on Zacks Earnings Calendar.

The renowned diagnostics provider posted adjusted earnings per share (EPS) of $2.30 in the last reported quarter, which surpassed the Zacks Consensus Estimate by 1.77%. The company topped earnings estimates in each of the trailing four quarters, the average surprise being 3.41%.

DGX’s Q4 Estimates

For the fourth quarter of 2024, the Zacks Consensus Estimate for Quest Diagnostics’ revenues is pegged at $2.57 billion, indicating an increase of 12.4% from the year-ago reported figure.

The Zacks Consensus Estimate for the company’s fourth-quarter 2024 EPS suggests a 1.9% increase to $2.19.

Estimate Revision Trend Ahead of DGX’s Q4 Earnings

Estimates for Quest Diagnostics’ Q4 earnings have remained constant at $2.19 in the past 60 days.

Here’s a quick recap of the company’s performance leading up to this announcement.

Factors Likely to Influence DGX’s Q4 Performance

We anticipate impressive growth in the company’s Diagnostic Information Services (“DIS”) in the fourth quarter of 2024, driven by strong performances across the core physician and hospital channels. In physician lab services, Quest Diagnostics is likely to have benefited from new customer wins and expanded business, mainly due to the increased utilization of Advanced Diagnostics services. The company’s investments in these highly specialized offerings continue to scale innovations to improve patient care and drive growth.

Continuing the recent momentum, several clinical areas are likely to have delivered robust revenues in the fourth quarter. Brain health area growth may have been driven by the AD-Detect blood-based Alzheimer’s disease testing. In molecular genomics and oncology, DGX is likely to advance the broad national launch of the Haystack MRD (molecular residual disease) blood test. Women’s health revenues are likely to have been supported by strong demand for prenatal and hereditary genetic testing, as well as genital tract infections, including several STIs (sexually transmitted infections). The company may have witnessed high demand for tests that help physicians comprehensively screen for autoimmune disorders to speed diagnosis and expedite specialized care.

Quest Diagnostics Incorporated Price and EPS Surprise

Quest Diagnostics Incorporated price-eps-surprise | Quest Diagnostics Incorporated Quote

Quest Diagnostics’ string of acquisitions is also expected to have bolstered its performance in the to-be-reported quarter. The company completed the acquisition of select laboratory assets from OhioHealth in October 2024 and Alina Health the month before. The addition of LifeLabs may have helped the company grow in the Canadian market, which offers more favorable demographics than the United States.

Quest Diagnostics’ fourth-quarter top line is also expected to have been boosted by strong Medicare Advantage volume and revenue growth, as these plans focus on directing testing to high-quality, cost-efficient options like the company. It is likely to have continued to expand into new geographies through partnerships with health plans.

In Hospital lab services, the persistent staffing challenges for hospitals to fill specialized lab positions may have continued to drive robust demand for the reference testing business. The dynamic is prompting hospitals to take advantage of Quest Diagnostics’ expanding advanced diagnostics portfolio rather than building their in-house capabilities. The expansion of consumer-initiated tests on questhealth.com is likely to have generated strong revenues, along with an impressive repeat customer rate in the fourth quarter.

Going by our model, the company’s DIS revenues are likely to increase 11.7% year over year in the to-be-reported quarter.

Operationally, Quest Diagnostics’ strategic use of automation and AI is likely to have played a key role in improving quality, service, efficiency and the workforce experience. Recent developments, such as the launch of the highly automated laboratory in Lenexa, KS, piloting of automated specimen accessioning in the Clifton lab, and the collaboration with Hologic to incorporate their AI-driven cytology solution are expected to have favorably boosted the performance in the fourth quarter of 2024. Finally, the company’s Invigorate program is expected to have met its targeted 3% in annual cost savings.

Our model projects Quest Diagnostics’ operating income and EBITDA (both on a non-GAAP basis) to improve by 20.7% and 20.1%, respectively, in the fourth quarter of 2024 compared to the last year.

What Our Model Unveils for DGX

Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see.

Earnings ESP: Quest Diagnostics has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: The company currently carries a Zacks Rank #2.

Top MedTech Picks

Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:

Masimo MASI has an Earnings ESP of +4.05% and a Zacks Rank #2. The company is set to release fourth-quarter 2024 results on Feb. 25. You can see the complete list of today’s Zacks #1 Rank stocks here.

MASI’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 17.10%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS is expected to increase 14.4% from the year-ago quarter figure.

Merit Medical Systems MMSI has an Earnings ESP of +3.03% and a Zacks Rank #2. The company is slated to release fourth-quarter 2024 results on Feb. 25.

MMSI’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.42%. The Zacks Consensus Estimate for Merit Medical’s fourth-quarter EPS is expected to increase by 2.47% from the year-ago quarter figure.

Exelixis EXEL has an Earnings ESP of +2.99% and a Zacks Rank #2. The company is expected to release fourth-quarter fiscal 2024 results on Feb. 4.

The company’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, with the average surprise being 26.52%. The Zacks Consensus Estimate for EXEL’s fourth-quarter EPS is expected to surge 51.5% from the year-ago reported figure.

Zacks Investment Research

Risk Warnings and Disclaimers

Add to Favorites

Astrana Health Repurchases About $10.6 Million of its Common Shares

MT Newswires

Astrana Health

-0.23%

Astrana Health said Tuesday it repurchased 300,000 of its common shares on Friday for $35.17 apiece or about a total purchase price of roughly $10.6 million.

The company purchased the shares from its shareholder Allied Physicians of California, it added.

Astrana Health's stock rose 3% in recent Tuesday trading.

Risk Warnings and Disclaimers

Add to Favorites

Dj Astrana Health Files 8K - Entry Into Definitive Agreement >Asth

Reuters

Astrana Health

-0.23%

Risk Warnings and Disclaimers

Add to Favorites

Daily News

Remarks of Officials

Central Bank

Forex

FastBull Events

FastBull Featured

Devin

Mohammad Omar

Recent Searches

Top Searches

Markets

News

Analysis

User

24/7

Economic Calendar

Education

Data

Quest Diagnostics (DGX) Q4 Earnings and Revenues Top Estimates

Apple, Visa, Intel set to report earnings Thursday, along with 100+ more

Officer Kumar Surrenders 7210 Of Astrana Health Inc [Asth]

Dj Officer Kumar Surrenders 7210 Of Astrana Health Inc >Asth

Quest Diagnostics Q4 Earnings Preview: What's in Store for the Stock?

Astrana Health Repurchases About $10.6 Million of its Common Shares

Dj Astrana Health Files 8K - Entry Into Definitive Agreement >Asth

Risk Disclosure